Composition
 One packet contains: active substance: phosphomycin trometamol 5,631 g in terms of phosphomycin - 3,000 g; auxiliary substances: calcium hydroxide - 0,300 g, lemon flavor - 0,200 g, sodium saccharin - 0,010 g, powdered sugar - up to 8,000 g.

pharmachologic effect
Phosphomycin is a broad-spectrum antibiotic of phosphonic acid. The bactericidal effect of phosphomycin is based on the fact that phosphomycin is a structural analogue of phosphoenol pyruvate. Inactivates N-acetyl-glucosamine-3-o-enolpyruvyl transferase, irreversibly blocks the condensation of uridine-diphosphate-M-acetyl-glucosamine with phosphoenol pyruvate, inhibits the synthesis of UDP-N-acetylmuric acid, thus inhibiting the initial stage of peptidoglycan formation of the bacterial cell wall. In vitro phosphomycin reduces the adhesion of a number of bacteria to the epithelium of the urinary tract. In vitro, Gram-positive (Staphylococcus saprophyticus, Enterococcus faecalis) and Gram-negative (Escherichia coli, Klebsiella pneumoniae, Citrobacter spp., Enterobacter spp., Proteus mirabilis) microorganisms are sensitive to phosphomycin. Inactivation of the enzyme N-acetyl-glucosamine-3-o-enolpyruvlevtransferase reduces the likelihood of cross-resistance to antibiotics with a similar mechanism of action and creates the conditions for synergy (in vitro experiments a synergistic effect with amoxicillin, cephalexin, pipemidic acid) was revealed.

Indications
Bacterial infections of the urinary tract of various locations caused by microorganisms susceptible to phosphomycin: acute uncomplicated urinary tract infections; asymptomatic bacteriuria; prevention of urinary tract infections after surgery and transurethral diagnostic studies.